A gene therapy just reversed aging signs in senior dogs

Old dogs make surprisingly good stand-ins for aging humans. They live in our homes, eat roughly what we eat, and get many of the same age-related diseases we do. A UK biotech called Genflow ran a gene therapy trial on senior beagles. The therapy delivers one gene, called SIRT6, that's linked to slowing aging in several species. Genflow said this week the trial hit its main goal: it measurably lowered the dogs' biological age.

The treated dogs survived longer than the untreated dogs. They also kept more physical function, during the dosing period studied so far. Genflow calls SIRT6 a "centenarian gene therapy." That's the company's own marketing name, not a scientific one. Full data won't be public until October. This is still a small biotech's early trial, not proof the therapy works in people. But dog aging research has a real track record. It predicts what might work in humans better than mouse studies do. That's because dogs age on a timeline much closer to ours.

Keep reading — what to watch

Will this actually translate to people? That's the real test still ahead. Human aging trials are slower, more expensive, and harder to measure than a dog study. Genflow's beagles are a promising early sign, not a finished answer.